AnnJi Pharmaceutical
CompanyTaiwan
AnnJi Pharmaceutical develops one asset, in phase 3 (rosolutamide in spinal and bulbar muscular atrophy). Mostly small molecule acting on Oxidative stress and ROS signalling, NRF2–KEAP1 antioxidant response and AR; based in Taiwan.
- 1
- Asset
- Furthest stage
- Phase 3
- 0
- Trials
- 0
- Signals
Pipeline
1Degrades mutant androgen receptor and induces Nrf2 and heat shock proteins
Phase 3, Small molecule, Oxidative stress and ROS signalling, NRF2–KEAP1 antioxidant response, spinal and bulbar muscular atrophy
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms5
- Similar companies6